|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||3.7000 - 3.7000|
|52-week range||1.0600 - 5.3500|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action. Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for rare and life-threatening diseases.
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. ("Acer" or the "Company") (NASDAQ: ACER) concerning whether the board breached its fiduciary duties to shareholders.